London, United Kingdom: Patients suffering from insomnia experience sustained improvements in their sleep quality following the use of medical cannabis preparations, according to longitudinal data published in the journal Neuropsychopharmacology Reports.
British researchers assessed the use of botanical cannabis, oil extracts, and other authorized cannabis formulations in 126 patients enrolled in the UK Medical Cannabis Registry. (British healthcare specialists may prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Researchers assessed changes from baseline in patient-reported outcomes at one, three, six, 12, 18, and 24 months.
Consistent with prior studies, “CBMPs [cannabis-based medicinal preparations] were associated with statistically and clinically significant improvements in sleep quality at all timepoints up to 24 months.” Study participants also experienced sustained improvements in their anxiety. Fewer than ten percent of participants reported adverse events from cannabis, all of which were mild (e.g., dry mouth).
“The consistent, clinically significant improvements in sleep quality demonstrated by this study support the potential therapeutic use of CBMPs for insomnia,” the study’s authors concluded. “The results provide encouraging real-world evidence for the long-term utility of CBMPs. This is particularly promising since current conventional therapies such as Z-drugs and benzodiazepines have shown limited long-term efficacy. … RCTs [randomized controlled trials] are required to assess the long-term use of CBMPs for insomnia further to determine their true efficacy.”
Other observational studies assessing the use of cannabis products among patients enrolled in the UK Medical Cannabis Registry have reported them to be beneficial for those diagnosed with endometriosis, treatment-resistant epilepsy, cancer-related pain, anxiety, hypermobility disorders/Ehlers-Danlos syndrome, inflammatory bowel disease, insomnia, migraine, multiple sclerosis, osteoarthritis, substance use disorders and inflammatory arthritis, among other conditions.
Full text of the study, “UK Medical Cannabis Registry: A two-year prospective observational cohort study of clinical outcomes in insomnia,” appears in Neuropsychopharmacology Reports. Additional information on cannabis and insomnia is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
